Thompson Siegel & Walmsley LLC bought a new stake in Tandem Diabetes Care Inc (NASDAQ:TNDM) in the 1st quarter, Holdings Channel reports. The institutional investor bought 3,000 shares of the medical device company’s stock, valued at approximately $190,000.
Several other large investors have also recently modified their holdings of TNDM. Bremer Bank National Association acquired a new position in shares of Tandem Diabetes Care in the 1st quarter valued at approximately $31,000. PNC Financial Services Group Inc. acquired a new position in shares of Tandem Diabetes Care in the 4th quarter valued at approximately $44,000. IFP Advisors Inc raised its position in shares of Tandem Diabetes Care by 78.4% in the 4th quarter. IFP Advisors Inc now owns 1,757 shares of the medical device company’s stock valued at $66,000 after buying an additional 772 shares in the last quarter. Advisor Group Inc. raised its position in shares of Tandem Diabetes Care by 38.2% in the 4th quarter. Advisor Group Inc. now owns 2,351 shares of the medical device company’s stock valued at $89,000 after buying an additional 650 shares in the last quarter. Finally, Rockefeller Capital Management L.P. acquired a new position in shares of Tandem Diabetes Care in the 1st quarter valued at approximately $122,000. Institutional investors own 80.49% of the company’s stock.
In other Tandem Diabetes Care news, EVP Brian B. Hansen sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $72.00, for a total transaction of $720,000.00. Following the sale, the executive vice president now directly owns 11,381 shares of the company’s stock, valued at approximately $819,432. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP David B. Berger sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $67.76, for a total transaction of $135,520.00. Following the sale, the executive vice president now directly owns 5,311 shares in the company, valued at $359,873.36. The disclosure for this sale can be found here. Insiders have sold a total of 53,000 shares of company stock worth $3,505,580 over the last three months. Insiders own 6.90% of the company’s stock.
TNDM stock traded down $4.78 during trading on Monday, reaching $66.92. 1,587,650 shares of the company were exchanged, compared to its average volume of 1,132,183. The stock has a market cap of $4.16 billion, a price-to-earnings ratio of -26.24 and a beta of 0.51. Tandem Diabetes Care Inc has a twelve month low of $15.48 and a twelve month high of $74.81. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.43 and a quick ratio of 2.13.
Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings data on Tuesday, April 30th. The medical device company reported ($0.40) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.10). The company had revenue of $66.00 million for the quarter, compared to analyst estimates of $47.55 million. Tandem Diabetes Care had a negative return on equity of 40.76% and a negative net margin of 50.73%. Tandem Diabetes Care’s revenue for the quarter was up 141.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.82) earnings per share. On average, equities research analysts anticipate that Tandem Diabetes Care Inc will post -0.81 EPS for the current fiscal year.
Several equities analysts have recently commented on the stock. ValuEngine cut shares of Tandem Diabetes Care from a “strong-buy” rating to a “buy” rating in a research report on Monday, April 1st. Oppenheimer boosted their target price on shares of Tandem Diabetes Care from $68.00 to $80.00 and gave the company an “outperform” rating in a research report on Wednesday, May 1st. BidaskClub upgraded shares of Tandem Diabetes Care from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, June 5th. Craig Hallum restated a “buy” rating and issued a $84.00 target price (up from $70.00) on shares of Tandem Diabetes Care in a research report on Wednesday, May 1st. Finally, Bank of America reiterated a “neutral” rating and set a $65.00 price objective on shares of Tandem Diabetes Care in a research report on Friday, May 17th. Four research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Tandem Diabetes Care currently has an average rating of “Buy” and an average price target of $68.13.
TRADEMARK VIOLATION WARNING: This piece of content was reported by Highlight Press and is the property of of Highlight Press. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://highlightpress.com/2019/06/10/thompson-siegel-walmsley-llc-buys-new-stake-in-tandem-diabetes-care-inc-nasdaqtndm.html.
Tandem Diabetes Care Profile
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
Recommended Story: Technical Analysis
Want to see what other hedge funds are holding TNDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tandem Diabetes Care Inc (NASDAQ:TNDM).
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.